Skip to main content
Erschienen in: Medical Oncology 5/2015

01.05.2015 | Original Paper

Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis

verfasst von: Baoyong Sun, Fangxin Wang, Min Li, Mingshan Yang

Erschienen in: Medical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

To investigate the differences in gene expression level between metastatic and non-metastatic osteosarcoma (OS) samples and the potential mechanism. Gene expression profile data GSE9508 were downloaded from Gene Expression Omnibus database to identify the differentially expressed genes (DEGs) between metastatic, non-metastatic OS samples, and normal control samples via SAM method. Function expression matrix of the DEGs was constructed by calculating the functional node scores based on the genes sets collected from the pathways recorded in MsigDB database. Next, t test was applied to screen the differentially expressed functional nodes between each two kinds of samples. Finally, we compared the significant genes between selected DEGs and genes in differentially expressed functional nodes. There were 79 up-regulated DEGs between non-metastatic OS and normal samples, 380 up-regulated and 134 down-regulated DEGs between the metastatic OS and normal samples, and 761 up-regulated plus 186 down-regulated DEGs between metastatic and non-metastatic OS samples. A total of 3846 functional gene sets were collected to form the function expression profile matrix. The numbers of differentially expressed functional nodes between non-metastatic OS and normal samples, metastatic OS and normal samples, and metastatic and non-metastatic OS samples were 8, 39, and 5, respectively. The gene level difference between metastatic and non-metastatic OS samples can be distinguished using bioinformatics analysis. TGFB1, LFT3, KDM1A, and KRAS genes have the potential to be used as biomarkers for OS; however, further analysis is needed to verify the current results.
Literatur
1.
2.
Zurück zum Zitat Lim JS, Kim DH, Lee JA, Kim DH, Cho J, Cho WH, et al. Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma. J Pediatr Hematol Oncol. 2013;35(1):54–60.CrossRefPubMed Lim JS, Kim DH, Lee JA, Kim DH, Cho J, Cho WH, et al. Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma. J Pediatr Hematol Oncol. 2013;35(1):54–60.CrossRefPubMed
3.
Zurück zum Zitat Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a EUROCARE working group study. J Clin Oncol. 2005;23(16):3742–51.CrossRefPubMed Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a EUROCARE working group study. J Clin Oncol. 2005;23(16):3742–51.CrossRefPubMed
4.
Zurück zum Zitat Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1–2):247–63.CrossRefPubMed Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1–2):247–63.CrossRefPubMed
5.
Zurück zum Zitat Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422–41.CrossRefPubMed Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422–41.CrossRefPubMed
6.
Zurück zum Zitat Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415–20.CrossRefPubMed Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415–20.CrossRefPubMed
7.
Zurück zum Zitat Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer. 1997;79(2):245–54.CrossRefPubMed Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer. 1997;79(2):245–54.CrossRefPubMed
8.
Zurück zum Zitat Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65(6):2170–8.CrossRefPubMed Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65(6):2170–8.CrossRefPubMed
9.
Zurück zum Zitat Sørensen KD, Ørntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn. 2010;10(1):49–64.CrossRefPubMed Sørensen KD, Ørntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn. 2010;10(1):49–64.CrossRefPubMed
10.
Zurück zum Zitat Imoto S, Savoie CJ, Aburatani S, Kim S, Tashiro K, Kuhara S, et al. Use of gene networks for identifying and validating drug targets. J Bioinform Comput Biol. 2003;1(03):459–74.CrossRefPubMed Imoto S, Savoie CJ, Aburatani S, Kim S, Tashiro K, Kuhara S, et al. Use of gene networks for identifying and validating drug targets. J Bioinform Comput Biol. 2003;1(03):459–74.CrossRefPubMed
11.
Zurück zum Zitat Hutter B, Schaab C, Albrecht S, Borgmann M, Brunner NA, Freiberg C, et al. Prediction of mechanisms of action of antibacterial compounds by gene expression profiling. Antimicrob Agents Chemother. 2004;48(8):2838–44.CrossRefPubMedCentralPubMed Hutter B, Schaab C, Albrecht S, Borgmann M, Brunner NA, Freiberg C, et al. Prediction of mechanisms of action of antibacterial compounds by gene expression profiling. Antimicrob Agents Chemother. 2004;48(8):2838–44.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Wu C-J, Fu Y, Murali T, Kasif S. Gene expression module discovery using Gibbs sampling. Genome Inform. 2004;15(1):239-48.PubMed Wu C-J, Fu Y, Murali T, Kasif S. Gene expression module discovery using Gibbs sampling. Genome Inform. 2004;15(1):239-48.PubMed
13.
Zurück zum Zitat Yang X, Li H, Regan K, Li J, Huang Y, Lussier YA, editors. Towards mechanism classifiers: expression-anchored gene ontology signature predicts clinical outcome in lung adenocarcinoma patients. In: AMIA annu symp proc. American Medical Informatics Association; 2012. Yang X, Li H, Regan K, Li J, Huang Y, Lussier YA, editors. Towards mechanism classifiers: expression-anchored gene ontology signature predicts clinical outcome in lung adenocarcinoma patients. In: AMIA annu symp proc. American Medical Informatics Association; 2012.
14.
Zurück zum Zitat Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010;70(18):7063–72.CrossRefPubMed Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010;70(18):7063–72.CrossRefPubMed
15.
Zurück zum Zitat Qin S, Kim J, Arafat D, Gibson G. Effect of normalization on statistical and biological interpretation of gene expression profiles. Front Genet. 2012;3:160.CrossRefPubMedCentralPubMed Qin S, Kim J, Arafat D, Gibson G. Effect of normalization on statistical and biological interpretation of gene expression profiles. Front Genet. 2012;3:160.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Liew AW, Law NF, Yan H. Missing value imputation for gene expression data: computational techniques to recover missing data from available information. Brief Bioinform. 2011;12(5):498–513.CrossRefPubMed Liew AW, Law NF, Yan H. Missing value imputation for gene expression data: computational techniques to recover missing data from available information. Brief Bioinform. 2011;12(5):498–513.CrossRefPubMed
17.
Zurück zum Zitat Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, et al. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012;8(1):e1002350.CrossRefPubMedCentralPubMed Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, et al. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012;8(1):e1002350.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1–2):279–84.CrossRefPubMed Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1–2):279–84.CrossRefPubMed
19.
Zurück zum Zitat Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, et al. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate. 2009;69(11):1222–34.CrossRefPubMed Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, et al. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate. 2009;69(11):1222–34.CrossRefPubMed
20.
Zurück zum Zitat Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, et al. Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells. 2013;31(3):433–46.CrossRefPubMed Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, et al. Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells. 2013;31(3):433–46.CrossRefPubMed
21.
Zurück zum Zitat Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol. 2012;28(4):201–12.CrossRefPubMed Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol. 2012;28(4):201–12.CrossRefPubMed
22.
Zurück zum Zitat Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43(8):1300–7.CrossRefPubMed Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43(8):1300–7.CrossRefPubMed
23.
Zurück zum Zitat Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest. 2013;123(11):4681–94.CrossRefPubMedCentralPubMed Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest. 2013;123(11):4681–94.CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Zhang S, Guo W, Ren TT, Lu XC, Tang GQ, Zhao FL. Arsenic trioxide inhibits Ewing’s sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs. 2012;23(1):108–18.CrossRefPubMed Zhang S, Guo W, Ren TT, Lu XC, Tang GQ, Zhao FL. Arsenic trioxide inhibits Ewing’s sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs. 2012;23(1):108–18.CrossRefPubMed
Metadaten
Titel
Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis
verfasst von
Baoyong Sun
Fangxin Wang
Min Li
Mingshan Yang
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0604-0

Weitere Artikel der Ausgabe 5/2015

Medical Oncology 5/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.